Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients
Plain-language summary
This Phase 2 trial is evaluating Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, and other medications as a treatment for people newly diagnosed with enteropathy-associated T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Newly diagnosed, not yet treated
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone) (DRUG): Induction Treatment: Golidocitinib:150mg QD Cyclophosphamide:750mg/m2，d1 vincristine:1.4mg/m2，d1(max 2mg) doxorubicin:50mg/m2，d1 Prednisone:60mg/m2 (max 100mg)，d1-d5 Every 21 days | Golidocitinib (DRUG): Maintenance Treatment: Complete remission patients will further divide into two groups. Unfit, frail old patients will receieve Golidocitinib 150mg QD for two years. Fit, young patients will receive ASCT.
- Drugs / treatments
- Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone), Golidocitinib
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details